---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336844"
form_type: "8-K"
ticker: "VIVS"
cik: "0001497253"
company_name: "VivoSim Labs, INC."
filed_at: "2026-08-06T12:05:23+00:00"
generated_at: "2026-08-06T12:10:28.798924+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# VivoSim regains Nasdaq equity compliance; cash $10.1M; guides 500%+ revenue growth in FY2027

## Summary
- Regained Nasdaq compliance (Rule 5550(b)(1)) after $5M Eli Lilly milestone and $4M financing.
- Cash on hand as of Aug 3, 2026: ~$10.1M, reflecting recent inflows.
- Reiterates FY2027 guidance of 500%+ revenue growth from NAMs contract research services.
- Share count rose from 3.2M (June 30) to 13.4M (Aug 3) on warrant exercises.
- Received $5M milestone from Eli Lilly, $1M escrow release, and $4M gross proceeds financing.

## SEC filing metadata
- accession: 0001193125-26-336844
- form_type: 8-K
- ticker: VIVS
- cik: 0001497253
- company_name: VivoSim Labs, INC.
- filed_at: 2026-08-06T12:05:23+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1497253/000119312526336844/0001193125-26-336844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1497253/000119312526336844/vivs-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336844
- JSON: https://secwatch.observer/filing/0001193125-26-336844.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.